



SWIXX BIOPHARMA PUBLISHES ESG STRATEGY FRAMEWORK

- *Leveraging a decade of growth and international presence in CEE, Eurasia, MENA and LATAM, we are committed to integrating Environmental, Social, and Governance (ESG) principles to enhance Swixx's business operations*
- *Our ESG strategy underscores our dedication to sustainable business practices, aiming to create lasting value for our stakeholders and the communities in which we operate.*

Baar, Switzerland, September 5th, 2024 – Swixx Biopharma is proud to announce the publication of its Environmental, Social, and Governance (ESG) Strategy Framework which is designed to measure the impact of our operations in the countries and communities in which we operate. Swixx's ESG Strategy Framework was developed with our stakeholders and incorporates both how Swixx's business is impacted by sustainability issues, and how Swixx's activities impact society and the environment. This sets the stage for our future detailed ESG report, transparently communicating our commitments, goals, progress, and milestones.

 **Jean-Michel Lespinasse, CEO of Swixx BioPharma** commented: "Following our expansion into the MENA and LATAM regions over the past several months, Swixx is evolving into one of the leading pharma commercialization platforms for multinational pharma companies. The ESG Strategy Framework represents another important step in our journey and reflects our business priorities and values. We are convinced that acting on ESG principles is the right path towards fulfilling Swixx's vision to become the preferred partner for biopharma seeking indirect routes to launch their medicines."

 **Barbara Košir, NED, Board Member, Ethics & Compliance Committee Chair and Audit Committee Chair, Lead of the ESG Green Team** at Swixx, stated: "At Swixx we see ESG not only as a future regulatory requirement, but as an opportunity to increase our transparency and accountability to ensure that we create a positive impact on the quality of life of our employees and people living in the communities where we operate as well as to minimize our environmental footprint. We firmly stand behind our direction to make a meaningful contribution across all 5 key areas of our ESG strategy."

About Swixx ESG Framework

Our priorities are reflected in 5 ESG building blocks that form the core of our sustainability strategy and support the achievement of the UN Sustainable Development Goals.

1. Put People First by promoting collaboration, well-being, safety, diversity, inclusion, and equity in the workplace.
2. Ensure Access to Medicines and a reliable supply of innovative products from our partners, unlocking access to the best medical solutions and contributing to a healthier future for all.



3. Strengthen Community Partnerships by empowering patient advocacy groups and collaborating with all relevant stakeholders dedicated to enhancing health management, healthcare accessibility, and improving health outcomes.
4. Preserve the Environment by implementing sustainable practices to minimize our environmental footprint, including responsible waste management and optimization of the car-fleet carbon footprint.
5. Foster Sustainable Corporate Governance: Swixx is committed to the highest standards of ethics, compliance and corporate governance.

These building blocks and goals challenge us to deliver positive social, environmental, and economic outcomes. Each pillar has defined specific goals and milestones that direct our efforts and guide our activities to support the responsible delivery of our business strategy. By integrating ESG into our corporate strategy, Swixx is committed to creating sustainable value for our stakeholders and contributing positively to society and the environment, helping ensure a better and healthier future for all.

For more information about our ESG Framework and to view our detailed report, please visit https://www.swixxbiopharma.com/en/environment_social_governance_esg/.

About Swixx BioPharma AG

Swixx BioPharma is one of the fastest-growing, largest, intercontinental commercial platforms for the biopharmaceutical industry. Swixx operates subsidiaries across Central and Eastern Europe, Greece, Russia, several Eurasian countries, the Middle East, and via Biopas, a Swixx BioPharma company, in almost 20 Latin American countries. Swixx BioPharma Group has over 1,600 employees and sales likely to exceed a billion Euros in 2024. The company has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof. For more information about Swixx BioPharma, please visit: www.swixxbiopharma.com.



Contact:

Vedrana Sokac Brataljenovic, Public Affairs Director,

vedrana.sokac@swixxbiopharma.com, Tel: +385 1 425 6086

